Stroke
Conditions
Brief summary
Variation (Δ) in the amplitude of the motor evoked potential (MEP) induced by a Paired Associative Stimulation (PAS) protocol, expressed as the percentage change between pre-PAS and post-PAS measurements, assessed at each session
Detailed description
Cortical excitability (TMS): resting motor threshold, MEP amplitude and latency, assessed at each session., Motor learning performance: learning effect, rebound, and retention on SRTT and Target Jump tasks, assessed at each session., Safety: spontaneous report on adverse events, assessed at each session, Severity of the symptom that led to treatment prescription reported by the patient using the Patient Global Impression of Severity (PGI-S)
Interventions
DRUGLIORÉSAL 10 mg
DRUGcomprimé sécable
DRUGNEURONTIN 100 mg
DRUGgélule
DRUGNEURONTIN 300 mg
DRUGNEURONTIN 400 mg
DRUGSERESTA 10 mg
DRUGcomprimé
Sponsors
Centre Hospitalier Universitaire De Toulouse
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Variation (Δ) in the amplitude of the motor evoked potential (MEP) induced by a Paired Associative Stimulation (PAS) protocol, expressed as the percentage change between pre-PAS and post-PAS measurements, assessed at each session | — |
Secondary
| Measure | Time frame |
|---|---|
| Cortical excitability (TMS): resting motor threshold, MEP amplitude and latency, assessed at each session., Motor learning performance: learning effect, rebound, and retention on SRTT and Target Jump tasks, assessed at each session., Safety: spontaneous report on adverse events, assessed at each session, Severity of the symptom that led to treatment prescription reported by the patient using the Patient Global Impression of Severity (PGI-S) | — |
Outcome results
None listed